News & Updates

Biomarker-informed molecular guidance improves anti-TNF therapy outcomes in patients with inflammatory bowel disease (IBD), increasing the likelihood of achieving disease control when compared with standard “best care,” as shown in the GUIDE-IBD trial.

The next-generation oral full-spectrum microbiome drug EBX-102-02 appears to have an acceptable safety profile in patients with irritable bowel syndrome with constipation (IBS-C) while yielding improvements in symptom severity, abdominal pain, and stool consistency, according to the results of the phase IIa TrIuMPH* study.

The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.

The selective PPARδ* agonist seladelpar continues to demonstrate benefit in patients with primary biliary cholangitis (PBC) in the long-term pooled analysis from the ongoing open-label phase III ASSURE trial.